Vyne Therapeutics will hand its Nasdaq spot to RTW’s Yarrow Bioscience in a reverse merger that will also bring a $200 million cash infusion into the biotech. The all-stock transaction

The FDA wants Novo Nordisk to analyze all sites it bought from Catalent last year, according to a warning letter the agency sent to the drugmaker over its troubled factory in Bloomington, IN. The …

Plus, news about Neurocrine, TargED, T-CURX, Immunome and Kodiak: 🤝 Vir Biotechnology’s licensing deal: An affiliate of Norgine Pharma will take the commercial rights to the experimental chronic hepatitis delta combo

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD’s Keytruda as perioperative therapy for muscle-invasive bladder cancer.

Chris Bahl saw the writing on the wall for his new AI startup in the final weeks of 2022: Molecules would matter more than models. A pair of preprints had just come out, both showing …

The Endpoints Winners and Losers list is back — and we’re bringing it to Post-Hoc Live on Thursday (that’s tomorrow) at 12 p.m. ET. The list is our now-annual tradition, tracking who was up and who was down in biopharma and health tech, and we’ve debated our picks, checked our list twice, and on Thursday […]

Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.

The challenging and competitive field of gene insertion has another well-funded contender. Addition Therapeutics, a startup based on research from the University of California, Berkeley, has raised $106.5 million for a new way to install …

LIB Therapeutics has won FDA approval for a once-monthly cholesterol drug, Lerochol, that it says offers ease-of-use advantages over rivals.